Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma.
This short review offers an update on the first and second Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) for patients with melanoma, and briefly traces the development of intraoperative lymphatic mapping and sentinel node biopsy.
John Wayne Cancer Institute, 2200 Santa Monica Blvd., Santa Monica, CA 90404, USA. mortond@JCWI.org
Donald L
DL
Morton
D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis / Q000175:diagnosis*; D008545:Melanoma / Q000473:pathology* / Q000601:surgery; D011788:Quality of Life; D021701:Sentinel Lymph Node Biopsy; D012878:Skin Neoplasms / Q000473:pathology* / Q000601:surgery; D013534:Survival